Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1,-adrenergic receptors in vitro

被引:161
作者
Bymaster, FP [1 ]
Nelson, DL [1 ]
DeLapp, NW [1 ]
Falcone, JF [1 ]
Eckols, K [1 ]
Truex, LL [1 ]
Foreman, MM [1 ]
Lucaites, VL [1 ]
Calligaro, DO [1 ]
机构
[1] Lilly Corp Ctr, Lilly Res Labs, Neurosci Res Div, Indianapolis, IN 46285 USA
关键词
olanzapine; clozapine; psychosis; schizophrenia; antipsychotic; dopamine; norepinephrine; muscarinic;
D O I
10.1016/S0920-9964(98)00146-7
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The atypical antipsychotic olanzapine has relatively high affinity for a number of neuronal receptors in radioreceptor binding assays. The ability of olanzapine to activate or antagonize a number of neuronal receptors was investigated in vitro, in cell lines transfected selectively with receptor subtypes and in receptor-selective isolated tissue studies. Olanzapine had no agonist activity at any of the receptors examined. However, olanzapine was a potent antagonist of 5-HT-stimulated increases in IP3 in cell lines transfected with 5-HT2A or 5-HT2B receptors with IC50 values of 30-40 nM. Olanzapine weakly blocked 5-HT-induced formation of IP3 in cell lines transfected with 5-HT2C receptors, but in this cell line potently inhibited 5-HT-stimulated [S-35]GTP gamma S binding with a K-i value of 15 nM. Olanzapine blocked dopamine-stimulated adenylyl cyclase in rat retina with modest potency (K-i=69 nM), consistent with its relatively low affinity for dopamine D1 receptors. Olanzapine blocked agonist-induced activities at the muscarinic receptor subtypes M-1, M-2, M-3, and M-5 with K-i values of 70, 622, 126, and 82 nM, respectively. In studies using cell lines transfected with muscarinic M-4 receptors, olanzapine and the atypical antipsychotic clozapine did not have agonist activities as determined with cAMP inhibition and stimulation assays, arachidonic acid release and [S-35]GTP gamma S binding assays. However, olanzapine antagonized agonist-induced effects in muscarinic Mg cells with a Ki value of 350 nM. In isolated tissue studies, olanzapine potently blocked agonist-induced effects at alpha(1)-adrenergic and histamine H-1 receptors (K-B=9 and 19 nM, respectively). Thus, olanzapine was an antagonist at all receptors investigated and was a particularly potent antagonist at 5-HT2A, 5-HT2B, 5-HT2C, alpha(1)-adrenergic and histamine H-1 receptors. Olanzapine was a weaker antagonist at muscarinic and dopamine D1 receptors. (C) 1999 Elsevier Science B.V. AU rights reserved.
引用
收藏
页码:107 / 122
页数:16
相关论文
共 62 条
[1]   SOME ATYPICAL NEUROLEPTICS INHIBIT [H-3] SCH 23390 BINDING INVIVO [J].
ANDERSEN, PH ;
NIELSEN, EB ;
GRONVALD, FC ;
BRAESTRUP, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 120 (01) :143-144
[2]   Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence [J].
Arnt, J ;
Skarsfeldt, T .
NEUROPSYCHOPHARMACOLOGY, 1998, 18 (02) :63-101
[3]   DO CENTRAL ANTIADRENERGIC ACTIONS CONTRIBUTE TO THE ATYPICAL PROPERTIES OF CLOZAPINE [J].
BALDESSARINI, RJ ;
HUSTONLYONS, D ;
CAMPBELL, A ;
MARSH, E ;
COHEN, BM .
BRITISH JOURNAL OF PSYCHIATRY, 1992, 160 :12-16
[4]   COMPARISON OF 2ND-MESSENGER RESPONSES TO MUSCARINIC RECEPTOR STIMULATION IN M1-TRANSFECTED A9-L-CELLS [J].
BAUMGOLD, J ;
DYER, K ;
FALCONE, JF ;
BYMASTER, FP .
CELLULAR SIGNALLING, 1995, 7 (01) :39-43
[5]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[6]   THE EFFECT OF CLOZAPINE ON PLASMA NOREPINEPHRINE - RELATIONSHIP TO CLINICAL EFFICACY [J].
BREIER, A ;
BUCHANAN, RW ;
WALTRIP, RW ;
LISTWAK, S ;
HOLMES, C ;
GOLDSTEIN, DS .
NEUROPSYCHOPHARMACOLOGY, 1994, 10 (01) :1-7
[7]   Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha(1)-adrenergic and muscarinic receptors in vivo in rats [J].
Bymaster, FP ;
HemrickLuecke, SK ;
Perry, KW ;
Fuller, RW .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :87-94
[8]   Radioreceptor binding profile of the atypical antipsychotic olanzapine [J].
Bymaster, FP ;
Calligaro, DO ;
Falcone, JF ;
Marsh, RD ;
Moore, NA ;
Tye, NC ;
Seeman, P ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :87-96
[9]  
Bymaster FP, 1997, J CLIN PSYCHIAT, V58, P28
[10]   Olanzapine increases extracellular dopamine release and blocks dopamine, serotonin and muscarinic receptors in vivo [J].
Bymaster, FP ;
Li, XM ;
Carter, PA ;
Wong, DT ;
Perry, KW .
SCHIZOPHRENIA RESEARCH, 1997, 24 (1-2) :74-74